Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase 2 Trial Testing the Addition of Upfront Stereotactic Radiosurgery to Binimetinib Encorafenib Pembrolizumab Compared to Binimetinib Encorafenib Pembrolizumab Alone in BRAFV600 Mutation-positive Melanoma With Brain Metastasis

NCT04074096 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04074096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase 2 Trial Testing the Addition of Upfront Stereotactic Radiosurgery to Binimetinib Encorafenib Pembrolizumab Compared to Binimetinib Encorafenib Pembrolizumab Alone in BRAFV600 Mutation-positive Melanoma With Brain Metastasis
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 5, 2022
Completion date
March 27, 2027
Enrollment
10 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, brain metastases, malignant melanoma